SA519402443B1 - تركيبات جديدة واستخدامها لعلاج الاضطرابات المناعية - Google Patents

تركيبات جديدة واستخدامها لعلاج الاضطرابات المناعية Download PDF

Info

Publication number
SA519402443B1
SA519402443B1 SA519402443A SA519402443A SA519402443B1 SA 519402443 B1 SA519402443 B1 SA 519402443B1 SA 519402443 A SA519402443 A SA 519402443A SA 519402443 A SA519402443 A SA 519402443A SA 519402443 B1 SA519402443 B1 SA 519402443B1
Authority
SA
Saudi Arabia
Prior art keywords
extract
ipolamide
compounds
plant biomass
ibolamide
Prior art date
Application number
SA519402443A
Other languages
Arabic (ar)
English (en)
Inventor
ماسكاريلو اليساندرا
دراجاني ريس رومولو
هنريك دي سوزا جاما فرناندو
إدواردو فيتور كارلوس
روش ويرنيك جيماريس كريستيانو
رافانيلي بيسا ليساندرا
Original Assignee
أشي لابوراتوريوس فارماكوتيكوس اس. أ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by أشي لابوراتوريوس فارماكوتيكوس اس. أ. filed Critical أشي لابوراتوريوس فارماكوتيكوس اس. أ.
Publication of SA519402443B1 publication Critical patent/SA519402443B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
SA519402443A 2017-02-17 2019-08-15 تركيبات جديدة واستخدامها لعلاج الاضطرابات المناعية SA519402443B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102017003318-0A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas

Publications (1)

Publication Number Publication Date
SA519402443B1 true SA519402443B1 (ar) 2023-02-08

Family

ID=61282932

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519402443A SA519402443B1 (ar) 2017-02-17 2019-08-15 تركيبات جديدة واستخدامها لعلاج الاضطرابات المناعية

Country Status (28)

Country Link
US (1) US12698265B2 (cg-RX-API-DMAC7.html)
EP (2) EP3583103B1 (cg-RX-API-DMAC7.html)
JP (2) JP7349362B2 (cg-RX-API-DMAC7.html)
KR (2) KR102882868B1 (cg-RX-API-DMAC7.html)
CN (1) CN110475768B (cg-RX-API-DMAC7.html)
AU (2) AU2018221956B2 (cg-RX-API-DMAC7.html)
BR (1) BR102017003318A2 (cg-RX-API-DMAC7.html)
CA (2) CA3052713A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008891A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125187T1 (cg-RX-API-DMAC7.html)
DK (1) DK3583103T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP19058322A (cg-RX-API-DMAC7.html)
ES (1) ES2909387T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220377T1 (cg-RX-API-DMAC7.html)
IL (2) IL268732B2 (cg-RX-API-DMAC7.html)
LT (1) LT3583103T (cg-RX-API-DMAC7.html)
MX (2) MX2019009655A (cg-RX-API-DMAC7.html)
PE (2) PE20242300A1 (cg-RX-API-DMAC7.html)
PL (1) PL3583103T3 (cg-RX-API-DMAC7.html)
PT (1) PT3583103T (cg-RX-API-DMAC7.html)
RS (1) RS63162B1 (cg-RX-API-DMAC7.html)
SA (1) SA519402443B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907375VA (cg-RX-API-DMAC7.html)
SI (1) SI3583103T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200121T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018148816A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201906106B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
IL57433A (en) * 1978-06-03 1982-08-31 Inst Rech Chim Biolog Pharmaceutical compositions containing cyclopentane derivatives
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
AU651849B2 (en) * 1990-10-09 1994-08-04 Tsumura & Co. Iridoid derivatives and their use as medicines
DE19644422C2 (de) 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1145709A1 (de) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen
DE60336549D1 (de) * 2002-05-10 2011-05-12 Council Scient Ind Res Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
US7501222B2 (en) * 2005-06-24 2009-03-10 Dongjin Semichem Co., Ltd. Photoresist monomer polymer thereof and photoresist composition including the same
JP2008024670A (ja) * 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
US8552210B2 (en) * 2006-12-21 2013-10-08 E I Du Pont De Nemours And Company Hydrogenation of catmint oil
BRPI0700767B8 (pt) 2007-02-15 2021-05-25 Ache Laboratorios Farmaceuticos Sa composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo
KR101406933B1 (ko) * 2011-09-02 2014-06-12 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699B (zh) * 2011-11-18 2017-04-19 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) * 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
DE102015102020A1 (de) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologisch aktives Phyto-Gemisch und seine Anwendung bei der Prävention und in einem Verfahren zur Behandlung von Effloreszenzen
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas

Also Published As

Publication number Publication date
JP2023061959A (ja) 2023-05-02
CO2019008891A2 (es) 2020-01-17
CN110475768A (zh) 2019-11-19
IL268732B2 (en) 2024-12-01
SMT202200121T1 (it) 2022-07-21
PE20242300A1 (es) 2024-12-11
CL2019002309A1 (es) 2020-05-29
CY1125187T1 (el) 2023-06-09
BR112019017128A2 (pt) 2020-04-14
EP3583103A2 (en) 2019-12-25
IL268732B1 (en) 2024-08-01
AU2018221956A1 (en) 2019-08-29
AU2022201835A1 (en) 2022-04-07
US20200231561A1 (en) 2020-07-23
IL313974A (en) 2024-08-01
JP7349362B2 (ja) 2023-09-22
KR20250145126A (ko) 2025-10-13
BR102017003318A2 (pt) 2018-10-30
ES2909387T3 (es) 2022-05-06
RU2019129095A3 (cg-RX-API-DMAC7.html) 2021-10-27
JP7685540B2 (ja) 2025-05-29
RU2019129095A (ru) 2021-03-17
AU2018221956B2 (en) 2022-03-24
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
KR102882868B1 (ko) 2025-11-07
JP2020507607A (ja) 2020-03-12
RS63162B1 (sr) 2022-05-31
DK3583103T3 (da) 2022-03-14
SG11201907375VA (en) 2019-09-27
AU2022201835B2 (en) 2024-05-30
PL3583103T3 (pl) 2022-08-01
MX2022012282A (es) 2022-10-27
KR20190121790A (ko) 2019-10-28
WO2018148816A3 (en) 2018-10-18
PT3583103T (pt) 2022-03-25
NZ756074A (en) 2025-10-31
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
WO2018148816A4 (en) 2019-01-03
CA3259255A1 (en) 2025-04-04
WO2018148816A2 (en) 2018-08-23
CA3052713A1 (en) 2018-08-23
US12698265B2 (en) 2026-08-04
MX2019009655A (es) 2020-07-24
ZA201906106B (en) 2020-08-26
PE20200449A1 (es) 2020-02-28
ZA202501840B (en) 2025-10-29
SI3583103T1 (sl) 2022-07-29
LT3583103T (lt) 2022-04-25
CN110475768B (zh) 2023-12-01
ECSP19058322A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
Nahata et al. Effect of Evolvulus alsinoides Linn. on learning behavior and memory enhancement activity in rodents
KR101762750B1 (ko) 무궁화의 꽃으로부터 추출된 정유를 포함하는 피부 재생용 외용제 및 화장료 조성물
Ghimire et al. Phytochemical constituents and pharmacological uses of medicinal plant Achyranthes aspera: a review.
Spessoto et al. Evaluation of the analgesic activity of extracts of Miconia rubiginosa (Melastomataceae)
JP7685540B2 (ja) 化合物、化合物の製造法、富化抽出物、富化抽出物の活性な分画、富化抽出物の製造法、富化抽出物を製造するため植物バイオマスを選択する方法、免疫障害を治療するための組成物とその利用
ES2886534T3 (es) Una composición para el tratamiento de la neuropatía, un procedimiento y un método de tratamiento de la misma
Aslam et al. Ulmus wallichiana Planchon: A vulnerable Himalayan native with immense medicinal value
RU2717963C1 (ru) Фитосредство, обладающее нормотимическим действием
HK40074103A (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders and vitiligo
RU2578453C1 (ru) Сбор лекарственных растений ноотропного действия
Tripatara et al. Effects of the polyherbal wattana formula on food intake, intestinal transit, and ileum contraction in Wistar rats
RU2180582C1 (ru) Обезболивающее средство
Karaca et al. Anti-inflammatory activities of diethyl-ether extracts of Helichrysum plicatum DC. and Tanacetum balsamita L. in rats
RU2568843C1 (ru) Средство, обладающее ноотропным действием
Rageeb et al. Chemical investigation and studies of analgesic and antipyretic activity of Moringa oleifera Lam. seeds extract
Коshovyi et al. Phytochemical and Pharmacological Research of the American Cranberry (Oxycoccus macrocarpus (Ait.) Pursh) Leaves Extract and its Aminoacids Preparation with Hepatoprotective Activity
Коshovyi et al. Article Not peer-reviewed version
CN104546829B (zh) 异木果楝素k及其类似物在制备抗抑郁症药物或食品中的用途
Devi ACUTE AND SUB ACUTE TOXICOLOGICAL EVALUATION OF ETHANOLIC EXTRACT OF HYPERICUM HOOKERIANUM
BR112019017128B1 (pt) Processo para produção de extrato enriquecido com derivados de ipolamida
Islam et al. Pharmacological Investigation on Ethanol Extract of Scindapsus hederaceus Miq.
Vani et al. ANTIHISTAMINIC AND ANTICHOLINERGIC STUDIES ON THE STEM EXTRACTS OF EUPHORBIA HETEROPHYLLA L.
Qureshi et al. International Journal of Green and Herbal Chemistry
BR122025011688A2 (pt) Compostos de fórmula (ii), uso de compostos de fórmula (ii), composição farmacêutica, processo para produção de extrato enriquecido com derivados de ipolamida da fórmula (ii), extratos de plantas do gênero stachytarpheta e uso dos extratos de plantas do gênero stachytarpheta
HK40011154B (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders